Scholarlink

Background <p><i>Non-tuberculous mycobacteria</i> (NTM) pose diagnostic and therapeutic challenges in tuberculosis (TB)-endemic regions like Jiangxi Province, China, due to clinical and radiological similarities to TB. This study elucidates the molecular epidemiology of NTM in Jiangxi (2021–2023).</p> Methods <p>A retrospective analysis of 20,724 clinical specimens from Jiangxi Chest Hospital was conducted using PCR-reverse blot hybridization assay (PCR-REBA) for NTM species identification. Inclusion required clinical/radiological suspicion of mycobacterial disease and specimens with sufficient volume (≥ 2 mL for liquid samples or ≥ 0.5&#xa0;g for tissue). Statistical analyses determined prevalence, species distribution, and predictors.</p> Results <p>Among 5,331 Mycobacterium-positive specimens, 333 (1.60%; 95% CI: 1.43–1.77) were NTM. Males had significantly lower odds of infection than females (aOR 0.499, <i>P</i> &lt; 0.001), with the highest prevalence observed in individuals aged ≥ 65 years (2.64%) compared to the ≤ 24 years reference group (aOR 12.922, 95% CI: 5.288–31.578, <i>P</i> &lt; 0.001). Dominant species were <i>Mycobacterium intracellulare</i> (MIN, 51.7%), <i>Mycobacterium abscessus</i> (MAB, 30.9%), and <i>Mycobacterium avium</i> (MAV, 9.3%). MIN and MAB predominated in pulmonary samples (97.9% of cases), while MAV showed significant extrapulmonary tropism (42.9% vs. 8.6% pulmonary, <i>P =</i> 0.02). Detection rates fluctuated temporally (peak: 1.93% in 2021; trough: 1.20% in 2022; <i>P =</i> 0.004), potentially influenced by the COVID-19 pandemic.</p> Conclusion <p>Jiangxi exhibits a distinct NTM profile with elevated MAB prevalence, emphasizing the need for species-level diagnosis to prevent misclassification as multidrug-resistant TB. Age, sex, and temporal trends emphasizing the critical need for species-level identification to facilitate early, targeted antimicrobial therapy and prevent the misclassification of NTM as multidrug-resistant TB.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Molecular epidemiology of non-tuberculous mycobacteria in clinical samples from Jiangxi Province, 2021–2023

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月16日

查看全文
  • Zhan Qiu Mao,
  • Huilie Zheng,
  • Hui Qiong Yang,
  • Qian Zhong Liu,
  • Yu Hong Xiong,
  • Zhen Qiong Liu,
  • Qi Long Zhang

摘要

Background

Non-tuberculous mycobacteria (NTM) pose diagnostic and therapeutic challenges in tuberculosis (TB)-endemic regions like Jiangxi Province, China, due to clinical and radiological similarities to TB. This study elucidates the molecular epidemiology of NTM in Jiangxi (2021–2023).

Methods

A retrospective analysis of 20,724 clinical specimens from Jiangxi Chest Hospital was conducted using PCR-reverse blot hybridization assay (PCR-REBA) for NTM species identification. Inclusion required clinical/radiological suspicion of mycobacterial disease and specimens with sufficient volume (≥ 2 mL for liquid samples or ≥ 0.5 g for tissue). Statistical analyses determined prevalence, species distribution, and predictors.

Results

Among 5,331 Mycobacterium-positive specimens, 333 (1.60%; 95% CI: 1.43–1.77) were NTM. Males had significantly lower odds of infection than females (aOR 0.499, P < 0.001), with the highest prevalence observed in individuals aged ≥ 65 years (2.64%) compared to the ≤ 24 years reference group (aOR 12.922, 95% CI: 5.288–31.578, P < 0.001). Dominant species were Mycobacterium intracellulare (MIN, 51.7%), Mycobacterium abscessus (MAB, 30.9%), and Mycobacterium avium (MAV, 9.3%). MIN and MAB predominated in pulmonary samples (97.9% of cases), while MAV showed significant extrapulmonary tropism (42.9% vs. 8.6% pulmonary, P = 0.02). Detection rates fluctuated temporally (peak: 1.93% in 2021; trough: 1.20% in 2022; P = 0.004), potentially influenced by the COVID-19 pandemic.

Conclusion

Jiangxi exhibits a distinct NTM profile with elevated MAB prevalence, emphasizing the need for species-level diagnosis to prevent misclassification as multidrug-resistant TB. Age, sex, and temporal trends emphasizing the critical need for species-level identification to facilitate early, targeted antimicrobial therapy and prevent the misclassification of NTM as multidrug-resistant TB.